Objective: We divided diabetic CKD patients into two groups: CKD stage 3 (CKD 3, n=14), CKD stage 4 (CKD 4, n=14) and CKD stage 5 (CKD 5, n=14). In this cross-sectional study, we performed comparative analysis with urine levels of GDF15 in patients with CKD stage. We recognized levels of these several biomarkers through the multiplexing using Luminex® technology. Urine GDF15 level was reported as a normalized ratio to urinary creatinine concentration Methods: Compared with the control group, urine GDF15  levels were higher in CKD 4 or CKD 5 group (10335 in control; 26183 in CKD 4;  34331 in CKD5 pg/ml). But, there were no statistically significant difference between control and CKD 3 group in urine GDF 15 (18124 pg/ml) . Urine GDF15 showed an increasing tendency in CKD 4 and CKD 5 group compared to CKD  3 group. However, there was no statistically significant difference. Plasma GDF15 level was significantly higher in the CKD 3, CKD 4 and CKD 5 group than that of control group (p<0.05) (Table 1). There was a significant correlation between serum and urine GDF 15 Results: The increased urine levels of GDF15 might be s biomarker of CKD in patients with diabetic CKD patients.  Conclusions: Objective: Diabetes mellitus (DM) and CKD are established as independent risk factors of vascular complications. From this perspective, the efforts to look for the plasma and urine biomarkers associated with endothelial injury in DM or CKD patients that result in vascular complications have been progressing. A relationship between Growth Differentiation Factor 15 (GDF15) and cardiovascular risk in diabetic patients was also reported. However, there were few reports about urine level of GDF15 in especially Korean patients with diabetic CKD, particularly.  Thus, we measured the serum and urine levels of GDF15 in patients with diabetic CKD patients Methods: We divided diabetic CKD patients into two groups: CKD stage 3 (CKD 3, n=14), CKD stage 4 (CKD 4, n=14) and CKD stage 5 (CKD 5, n=14). In this cross-sectional study, we performed comparative analysis with urine levels of GDF15 in patients with CKD stage. We recognized levels of these several biomarkers through the multiplexing using Luminex® technology. Urine GDF15 level was reported as a normalized ratio to urinary creatinine concentration Results: Compared with the control group, urine GDF15  levels were higher in CKD 4 or CKD 5 group (10335 in control; 26183 in CKD 4;  34331 in CKD5 pg/ml). But, there were no statistically significant difference between control and CKD 3 group in urine GDF 15 (18124 pg/ml) . Urine GDF15 showed an increasing tendency in CKD 4 and CKD 5 group compared to CKD  3 group. However, there was no statistically significant difference. Plasma GDF15 level was significantly higher in the CKD 3, CKD 4 and CKD 5 group than that of control group (p<0.05) (Table 1). There was a significant correlation between serum and urine GDF 15 Conclusions: The increased urine levels of GDF15 might be s biomarker of CKD in patients with diabetic CKD patients.